Douglas Flora: Our shared mission of AI, to fight cancer, drives us forward every day
Douglas Flora recently shared a post on LinkedIn:
“Our shared mission—to harness the power of artificial intelligence to fight cancer and improve patient outcomes—drives us forward every day. To continue making strides in this vital field, we invite your active participation with AI in Precision Oncology and Inside Precision Medicine.
Your work is the cornerstone of our progress, and sharing your discoveries and support helps push the boundaries of what’s possible with AI in precision oncology.
AI in Precision Oncology is a peer-reviewed journal, dedicated to advancing artificial intelligence applications in clinical and precision oncology.
Submit, Subscribe, Support (Share?)
With an editorial board composed of a diverse and accomplished team of international experts, the journal provides a high-profile forum for cutting-edge research and industry advances across the field, from basic research to clinical implementation.
AI in Precision Oncology enables professionals in the field of oncology to understand how AI and technology solutions can be applied effectively to benefit healthcare providers and advance patient care.
We welcome top-quality, science-driven research and reviews for rapid peer review and publication.
Tell your story to our engaged community of over 300,000 hospital and pharma leaders, oncologists, physicians, pathologists, genetic counselors, nurse navigators, clinical researchers, and patient advocacy groups.”
Read further
Source: Douglas Flora/LinkedIn
Douglas Flora is the Executive Medical Director of Oncology Services at St. Elizabeth Healthcare, overseeing clinical operations, strategic planning, and the expansion of cancer programs. He is also the co-founder of the Center for Precision Medicine & Genomic Health.
As the Editor-in-Chief of ‘AI in Precision Oncology,’ the first peer-reviewed academic journal dedicated to this field, he plays a pivotal role in advancing research. He is also an active board member of the American Cancer Society and ACCC, where he contributes to advocacy, education, and innovation within the cancer community.